Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Kivu Bioscience Inc.
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Eli Lilly and Company
The Netherlands Cancer Institute
Parabilis Medicines, Inc.
Actuate Therapeutics Inc.
Memorial Sloan Kettering Cancer Center
Hoffmann-La Roche
Erasca, Inc.
National Cancer Institute (NCI)